MHRA Alerts Patients on Lercanidipine Labelling Error

A batch of the blood pressure medication Lercanidipine HCl 20mg, manufactured by Recordati Pharmaceuticals, has been incorrectly labelled as 10mg on some sides of the packaging, though the correct 20mg dose is printed on the top of the carton and on the blister strips. The Medicines and Healthcare products Regulatory Agency (MHRA) has issued an alert and a recall for the affected batch (MD4L07, expiry 01/2028), urging patients and pharmacists to check the packaging and not to supply or use medicine from this batch. Patients prescribed 10mg who have received tablets from this batch are advised to contact their pharmacist or GP immediately; if unable to do so, they should verify the tablet strength from the blister strip and, as a temporary measure, take half of a 20mg tablet as per the patient leaflet instructions. Those prescribed 20mg should confirm the dose on the blister before taking their medication and continue as directed by their doctor. Patients should not stop taking their medication without consulting a healthcare provider, and anyone concerned about having taken an incorrect dose should contact a pharmacist, doctor, or NHS 111. The MHRA emphasizes that patient safety is the priority and encourages reporting of any adverse reactions.